Understand the clinical requirements and patient experience during a supervised Spravato visit in certified Maryland healthcare settings.
For adults in Maryland seeking advanced therapies for difficult-to-treat depression, understanding the clinical requirements of specialized treatments is an important educational step. Spravato (esketamine) nasal spray requires a highly structured, supervised clinical visit. This article outlines what patients can expect during these supervised visits in Maryland, distinguishing FDA-approved protocols from other forms of care.
This information is intended for educational purposes only and does not constitute medical advice. Treatment plans and eligibility should always be discussed directly with a qualified healthcare professional.
Understanding Spravato's FDA Approval
Spravato is an FDA-approved prescription nasal spray. It is specifically indicated for adults with treatment-resistant depression (TRD) and for adults suffering from major depressive disorder with acute suicidal ideation or behavior. It is meant to be taken in conjunction with a daily oral antidepressant.
It is crucial to differentiate Spravato from other forms of ketamine. Formulations such as IV ketamine, oral troches, or compounded nasal sprays are considered off-label when used for psychiatric conditions. The FDA has raised concerns about the use of unapproved formulations; further details can be found in the FDA warning on compounded ketamine.
The Requirement for a Certified Setting
Unlike traditional daily antidepressants that you pick up at a pharmacy and take at home, Spravato is strictly controlled. There is no home Spravato allowed under any circumstances. It must be administered in a specialized, certified healthcare setting.
Throughout Maryland, from clinics in the busy corridors of Central Maryland to specialized practices in Western Maryland, facilities offering this treatment must be certified to monitor patients safely. This ensures that healthcare providers are present to manage the medication and respond to any potential side effects promptly.
The Two-Hour Monitoring Period
When attending a Spravato appointment, patients must prepare to remain at the clinic for an extended period. The FDA mandates at least two hours of continuous clinical monitoring immediately following the administration of the nasal spray.
During this supervised window, healthcare providers will regularly check your vital signs, particularly your blood pressure, which can elevate after taking the medication. Providers also monitor for signs of dissociation or sedation. Clinics generally design their monitoring rooms to be calm, quiet, and comfortable, allowing patients to rest safely while the medical staff ensures their well-being. To learn more about the clinical data supporting these protocols, you can visit our research section.
Post-Treatment Discharge and Insurance
Once the two-hour monitoring period concludes and the healthcare provider determines that the patient is clinically stable, the patient may be discharged. As part of the safety protocol, patients are forbidden from driving or operating heavy machinery until the following day, after they have had a restful sleep. A designated driver is required to take the patient home, and these travel arrangements should be discussed thoroughly with the clinic beforehand.
Accessing this specialized treatment also requires navigating health insurance. Individual insurance coverage and prior authorization requirements must be checked carefully. Approval is not guaranteed, and coverage policies for Spravato differ entirely from coverage for off-label IV ketamine, which is rarely covered by standard insurance plans. Patients should work closely with their clinic's billing department and their insurance provider to understand their financial responsibilities before beginning treatment.
By understanding the strict guidelines—from the certified setting to the mandatory observation period—patients can better prepare for their treatment journey.
Editorial source check November 4 2026 not clinician review.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.